Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 30

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 30
---
-1236, receive regulatory and marketing approval
and are commercialized, and we may never be successful in obtaining regulatory and marketing approval and commercializing product candidates.
We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. These net losses will
adversely impact our stockholders’ equity and net assets and may fluctuate significantly from quarter to quarter and year to year.
We anticipate that our expenses will increase substantially as we:

| ● | continue our ongoing and                                                    
 planned R&D activities for our CER-T cell therapies and product candidates; |

| ● | pursue preclinical studies                                                              
 and initiate clinical trials for our CER-T cell therapies and other product candidates; |

| ● | seek to discover and develop                                           
 additional product candidates and further expand our product pipeline; |

| ● | seek regulatory and marketing                                                    
 approvals for any product candidates that successfully complete clinical trials; |

| ● | establish sales, marketing                                                                                          
 and distribution infrastructure to commercialize any product candidate for which we may obtain regulatory approval; |

| ● | develop and refine the                            
 manufacturing process for our product candidates; |

| ● | change or add additional                                                  
 manufacturers or suppliers of biological materials or product candidates; |

| ● | establish or supplement                                             
 relationships with CDMOs, CROs and other third party collaborators; |

| ● | develop, maintain, expand                        
 and protect our intellectual property portfolio; |

| ● | acquire or in-license other          
 product candidates and technologies; |

| ● | hire clinical, quality               
 control and manufacturing personnel; |

| ● | add clinical, operational,                                                                                                            
 financial and management information systems and personnel, including personnel to support our product development and planned future 
 commercialization efforts; and                                                                                                        |

| ● | incur additional legal,                                                      
 accounting and other expenses associated with operating as a public company. |

To become and remain profitable,
we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful
in a range of challenging activities, including completing preclinical studies and clinical trials for our product candidates, preparing
a satisfactory filing package for regulatory authorities, obtaining regulatory approval, manufacturing, marketing and selling any products
for which we may obtain regulatory approval, as well as discovering and developing additional product candidates. We may never succeed
in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability.

Because of the numerous
risks and uncertainties associated with the development, manufacturing, delivery and commercial